Gilead Sciences Inc
(BUE:GILD)
ARS
26600
125 (0.47%)
Market Cap: 111.51 Tn
Enterprise Value: 131.94 Tn
PE Ratio: 110.08
PB Ratio: 6.15
GF Score: 52/100 Gilead Sciences Inc at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019 / 02:00PM GMT
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director
Great. So good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Just quickly, before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures or you can pick up a copy at the registration desk.
So very pleased to have with me Dan O'Day, the Chairman and CEO from Gilead. And Dan, I don't think you want to make any opening remarks, do you want to?
Daniel O;Day
Gilead Sciences, Inc. - Chairman & CEO
' -
No. We'll go right in.
Matthew Kelsey Harrison;Daniel O;Day
Morgan Stanley, Research Division - Executive Director;Gilead Sciences, Inc. -
All right. So I think we'll go right.
'
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot